Corona Remedies’ IPO opened with decent subscription demand, led by strong retail demand and a robust Rs 290 grey-market premium. The Rs 655-crore issue, priced at Rs 1,008–1,062, signals healthy investor interest ahead of the December 10 close and expected December 15 listing.